擅長領(lǐng)域：主要從事腫瘤綜合治療；腸癌、肺癌、乳腺癌等常見腫瘤的內(nèi)科治療（尤其是靶向治療）；VIP病人保健和管理。?

執(zhí)業(yè)經(jīng)歷： 腫瘤學(xué)博士，主任醫(yī)師，博士生導(dǎo)師，中山大學(xué)腫瘤防治中心綜合科科室副主任。主要從事腫瘤綜合治療；腸癌、肺癌、乳腺癌等常見腫瘤的內(nèi)科治療（尤其是靶向治療）；VIP病人保健和管理。至今發(fā)表科研論文146篇，其中第一作者/通訊作者95篇（包括56篇SCI論文），包括J Clin Invest；Nat Commun；Clin Cancer Res；J Immunother Cancer；Mol Ther；JNCCN；Int J Cancer；Aging；J Transl Med；Sci Rep等雜志。主持14項(xiàng)科研基金，包括3項(xiàng)國家自然科學(xué)基金。 　　另外，承擔(dān)全院“靜脈輸液港植入術(shù)”，至今有近1000例植入術(shù)經(jīng)驗(yàn)，并成功舉辦四期“靜脈輸液港植入術(shù)和護(hù)理技術(shù)培訓(xùn)班”的廣東省繼續(xù)教育項(xiàng)目和一屆“海峽兩岸輸液港技術(shù)論壇”。 學(xué)習(xí)工作經(jīng)歷： 1989～1994 安徽醫(yī)科大學(xué)醫(yī)學(xué)系 1994～1996 安徽醫(yī)科大學(xué)第一附屬醫(yī)院外科 1996～1999 中山大學(xué)附屬第一醫(yī)院（碩士生） 1999～2002 中山大學(xué)附屬腫瘤醫(yī)院（博士生） 2002～ ? ? 中山大學(xué)附屬腫瘤醫(yī)院綜合科 科研經(jīng)歷： 一．基金 （一）第一負(fù)責(zé)人基金 1.中山大學(xué)腫瘤防治中心特支計(jì)劃：臨床科學(xué)家項(xiàng)目，2019，主持 2.中山大學(xué)腫瘤防治中心308項(xiàng)目：二甲雙胍聯(lián)合FOLFIRI二線治療非糖尿病RAS突變型轉(zhuǎn)移性結(jié)直腸癌的多中心、單臂Ⅱ期臨床研究，2019，主持 3.國家自然科學(xué)基金項(xiàng)目（81572409）：LDH預(yù)測bevacizumab治療轉(zhuǎn)移性結(jié)直腸癌療效的機(jī)制及新靶點(diǎn)的探索性研究。（2015） 4.國家自然科學(xué)基金項(xiàng)目（81272641）：同步干預(yù)2,3-DPG和PKM2在提高Bevacizumab治療腸癌療效中的關(guān)鍵作用。（2012） 5.國家自然科學(xué)基金項(xiàng)目（81071872）：Cetuximab通過下調(diào)SGLT1誘導(dǎo)腸癌細(xì)胞自噬性死亡是其抗腫瘤和增敏化療的新機(jī)制。（2010） 6.廣東省自然科學(xué)基金（2015A030313010）：AMPK/mTOR通路在cetuximab誘發(fā)腸癌細(xì)胞自噬過程中的作用與意義。（2015年） 7.廣州市科技計(jì)劃項(xiàng)目（1563000305）：Adenosine聯(lián)合siRNA-PKM2克服bevacizumab的“促癌作用”并提高其殺傷腸癌細(xì)胞能力的研究。（2015） 8.廣東省科技計(jì)劃項(xiàng)目（2011B061300069）：3-MA阻斷肺癌H460細(xì)胞自噬而提高Cetuximab+DDP抗腫瘤效應(yīng)。（2011） 9.廣東省科技計(jì)劃項(xiàng)目（2008B06060029）：siRNA抑制eIF4E后喉癌細(xì)胞株Hep2蛋白質(zhì)表達(dá)譜變化的研究。（2008年） 10.廣東省自然科學(xué)基金（9151008901000102）：不同p53背景下VX-680聯(lián)合Taxol殺傷鼻咽癌細(xì)胞的療效差異。（2009年） 11.廣東省衛(wèi)生廳項(xiàng)目：乳腺癌中Aurora-A表達(dá)與含Taxanes誘導(dǎo)化療方案療效關(guān)系的研究。（2008）。 12.“重大新藥創(chuàng)新”科技重大專項(xiàng)基金：自噬性細(xì)胞死亡在Cetuximab聯(lián)合Oxaliplatin/Irinotecan方案治療腸癌中的作用。（2008ZX09312－002）.? 13.廣東省衛(wèi)生廳基金：利用18FDG探測喉癌手術(shù)創(chuàng)面中腫瘤殘留狀況的研究。（B2004058） 14.中山大學(xué)腫瘤防治中心基金：利用18FDG探測喉癌手術(shù)創(chuàng)面中腫瘤殘留狀況的研究。（303041080562）。 （二）第二負(fù)責(zé)人基金 15.廣東省科技計(jì)劃項(xiàng)目（2010B031600317）：Cetuximab 下調(diào)SGLT1誘導(dǎo)腸癌細(xì)胞自噬為增敏Irinotecan的新機(jī)制（2010）。 16.廣東省衛(wèi)生廳基金（C2011019）：結(jié)直腸癌患者標(biāo)準(zhǔn)化與個(gè)體化治療相結(jié)合體系的建立與優(yōu)化（2012）。 17.廣東省科技計(jì)劃項(xiàng)目(20012137-C30305)：喉鱗癌手術(shù)切緣eIF4E、P53研究在喉功能保全性治療中的應(yīng)用。（2001）。 （三）第三負(fù)責(zé)人基金 18. 高等學(xué)校博士學(xué)科點(diǎn)專項(xiàng)科研基金（2000305）：同步高表達(dá)PFP、GrB 基因的喉癌TIL抗腫瘤作用的研究。（2000）。 二．文章 （一）第一作者/通訊作者論文(SCI) 1.Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, Wang X, Li M, Lu W, Zeng G, Zhou P, Huang P, Chen S, Li W, Xia LP（共同通訊）, Xia X. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Invest. 2019 Aug 13;130. pii: 127471. doi: 10.1172/JCI127471. 2.Guo G, Wang Y, Zhou Y, Quan Q, Zhang Y, Wang H, Zhang B, Xia L. Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes. J Immunother Cancer. 2019 Jul 12;7(1):179. doi: 10.1186/s40425-019-0656-3. 3.Guo GF, Wang YX, Zhang YJ, Chen XX, Lu JB, Wang HH, Jiang C, Qiu HQ, Xia LP. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data. World J Gastroenterol. 2019 Apr 21;25(15):1840-1853. doi: 10.3748/wjg.v25.i15.1840. 4.Jiang C, Wang F, Guo G, Dong J, Liu S, He W, Zhang B, Xia L.Metastatic lymph node ratio as a prognostic indicator in patients with stage IV colon cancer undergoing resection.J Cancer. 2019 Jun 2;10(11):2534-2540. 5.Kong P, Wang J, Song Z, Liu S, He W, Jiang C, Xie Q, Yang L, Xia X, Xia L.Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.J Cancer. 2019 Apr 5;10(7):1745-1754 6.Wu RY, Kong PF, Xia L（共一）, Huang Y, Li ZL, Tang YY, Chen Y, Li X, Senthilkumar R, Zhang HL, Sun T, Xu XL, Yu Y, Mai J, Peng XD, Yang D, Zhou LH, Feng GK, Deng R, Zhu XF. Regorafenib promotes anti-tumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma.Clin Cancer Res. 2019 Apr 2. pii: clincanres.2840.2018. doi: 10.1158/1078-0432.CCR-18-2840. [Epub ahead of print] 7.Quan Q, Zhu M, Liu S, Chen P, He W, Huang Y, Rong Y, Qiu H, Zhang B, Xia L. Positive impact of the negative lymph node count on the survival rate of stage III colon cancer with pN1 and right-side disease. J Cancer. 2019 Jan 29;10(4):1052-1059. 8.Liu S, Kong P, Wang X, Yang L, Jiang C, He W, Quan Q, Huang J, Xie Q, Xia X, Zhang B, Xia L.Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.Oncol Lett. 2019 Feb;17(2):2335-2343.? 9.Yang L, Yang X, He W, Liu S, Jiang C, Xie K, Peng K, You Y, Zhang B, Xia L.Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study.Aging (Albany NY). 2018 Dec 28. doi: 10.18632/aging.101700. [Epub ahead of print] 10.Yang L, He W, Xie Q, Liu S, Kong P, Jiang C, Zhang B, Xia L. Brain metastases in newly diagnosed colorectal cancer: a population-based study.Cancer Manag Res. 2018 Nov 15;10:5649-5658. 11.Wang F, He W, Jiang C, Guo G, Ke B, Dai Q, Long J, Xia L. Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer.BMC Cancer. 2018 Nov 12;18(1):1102. doi: 10.1186/s12885-018-4842-3. 12.Guo G, Chen X, He W, Wang H, Wang Y, Hu P, Rong Y, Fan L, Xia L.Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data.PLoS One. 2018 Dec 4;13(12):e0208547. 13.Xie QK, Chen P, Hu WM, Sun P, He WZ, Jiang C, Kong PF, Liu SS, Chen HT, Yang YZ, Wang D, Yang L, Xia LP.The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor.J Transl Med. 2018 Oct 4;16(1):273.? 14.Jiang C, Huang YH, Lu JB, Yang YZ, Rao HL, Zhang B, He WZ, Xia LP.Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer.Cancer Manag Res. 2018 Sep 17;10:3589-3597. 15.Yang L, Xiong Z, Xie QK, He W, Liu S, Kong P, Jiang C, Xia X, Xia L.Second primary colorectal cancer after the initial primary colorectal cancer.BMC Cancer. 2018 Sep 27;18(1):931.? 16.He WZ, Hu WM, Kong PF, Yang L, Yang YZ, Xie QK, Jiang C, Yin CX, Qiu HJ, Zhang B, Zhang HZ, Xia LP.Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value.J Cancer. 2018 Aug 6;9(17):3093-3100.? 17.Yang L, Xiong Z, He W, Xie K, Liu S, Kong P, Jiang C, Guo G, Xia L. Proximal shift of colorectal cancer with increasing age in different ethnicities.Cancer Manag Res. 2018 Aug 15;10:2663-2673. 18.He WZ, Yang QX, Xie JY, Kong PF, Hu WM, Yang L, Yang YZ, Xie QK, Jiang C, Yin CX, Guo GF, Qiu HJ, Zhang B, Xia LP.Association of low skeletal muscle index with increased systematic inflammatory responses and interferon γ-induced protein 10 levels in patients with colon cancer.Cancer Manag Res. 2018 Aug 7;10:2499-2507 19.Liu SS, Yang YZ, Jiang C, Quan Q, Xie QK, Wang XP, He WZ, Rong YM, Chen P, Yang Q, Yang L, Zhang B, Xia XJ, Kong PF, Xia LP.Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.J Transl Med. 2018 Jul 13;16(1):195. doi: 10.1186/s12967-018-1570-z. 20.He WZ, Xie QK, Hu WM, Kong PF, Yang L, Yang YZ, Jiang C, Yin CX, Qiu HJ, Zhang HZ, Zhang B, Xia LP.An increased number of negative lymph nodes is associated with a higher immune response and longer survival in colon cancer patients.Cancer Manag Res. 2018 Jun 18;10:1597-1604. 21.Xie QK, He WZ, Hu WM, Yang L, Jiang C, Kong PF, Yang YZ, Yang Q, Zhang HZ, Zhang B, Xia LP.Tumor-infiltrating lymphocyte as a prognostic biomarker in stage IV colorectal cancer should take into account the metastatic status and operation modality.Cancer Manag Res. 2018 May 30;10:1365-1375. 22.Yang L, Xiong Z, Xie Q, He W, Liu S, Kong P, Jiang C, Guo G, Xia L. Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer. BMC Cancer. 2018 May 11;18(1):558. doi: 10.1186/s12885-018-4431-5. 23.Jiang C, Cai X, Zhang H, Xia X, Zhang B, Xia L.Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.J Cancer. 2018 Jan 1;9(1):205-212. 24.Wang H, Peng R, Chen X, Jia R, Huang C, Huang Y, Xia L（共同通訊）, Guo G. Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer. Oncol Lett. 2018 Apr;15(4):5553-5560. 25.Yang L, He W, Kong P, Jiang C, Yang Q, Xie Q, Xia LP. Clinical baseline and prognostic difference of platelet lymphocyte ratio (PLR) in right-sided and let-sided colon cancers. BMC Cancer. 2017 Dec 20;17(1):873. doi: 10.1186/s12885-017-3862-8. 26.Yang L, He W, Yang Q, Kong P, Xie Q, Jiang C, Zhang B, Xia LP.Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer.Oncotarget. 2017 Oct 12;8(58):99136-99149.? 27.Kong P, Wu R, Lan Y, He W, Yang C, Yin C, Yang Q, Jiang C, Xu D, Xia L.Association between Mismatch-repair Genetic variation and the Risk of Multiple Primary Cancers: A Meta-Analysis.J Cancer. 2017 Sep 16;8(16):3296-3308. 28.Yang L, Xia L（共同第一）, Wang Y, He S, Chen H, Liang S, Peng P, Hong S, Chen Y.Development and external validation of nomograms to predict the risk of skeletal metastasis at the time of diagnosis and skeletal metastasis-free survival in nasopharyngeal carcinoma.BMC Cancer. 2017 Sep 6;17(1):628.? 29.Jiang C, Liu S, He W, Zhang B, Xia L. The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy. J Cancer. 2017 May 12;8(8):1410-1416. 30.Quan Q, Huang Y, Chen Q, Qiu H, Hu Q, Rong Y, Li T, Xia L, Zhang B.Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis. Transl Oncol. 2017 Apr;10(2):288-294. doi: 10.1016/j.tranon.2017.01.006. Epub 2017 Mar 2. 31.He WZ, Liao FX, Jiang C, Kong PF, Yin CX, Yang Q, Qiu HJ, Zhang B, Xia LP.Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients. J Cancer. 2017 Feb 10;8(3):388-394. 32.Kong P, Zhu X, Geng Q, Xia L（共同第一）, Sun X, Chen Y, Li W, Zhou Z, Zhan Y, Xu D.The microRNA-423-3p-Bim Axis Promotes Cancer Progression and Activates Oncogenic Autophagy in Gastric Cancer.Mol Ther. 2017 Feb 18. pii: S1525-0016(17)30020-5. doi: 10.1016/j.ymthe.2017.01.013. [Epub ahead of print] 33.Kong P, Wu R, Liu X, Liu J, Chen S, Ye M, Yang C, Song Z, He W, Yin C, Yang Q, Jiang C, Liao F, Peng R, Zhou Z, Xu D, Xia L.The Effects of Anti-inflammatory Drug Treatment in Gastric Cancer Prevention: an Update of a Meta-analysis.J Cancer. 2016;7(15):2247-2257. 34.Yin C, Ma G, Rong Y, Kong P, Yang Q, Jiang C, Liao F, Zhang B, He W, Xia L.The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer. J Cancer. 2016 Sep 13;7(13):1901-1906. 35.Kong P, Wu R, Yang C, Geng Q, Liu J, Chen S, Liu X, Ye M, He W, Yang Q, Xia L, Xu D. Prognostic Impact of the Signet Ring Cell Type in Node-Negative Gastric Cancer. Sci Rep. 2016;6:26313. doi: 10.1038/srep26313. 36.Yang L, Xia L, Wang Y, Hong S, Chen H, Liang S, Peng P, Chen Y. Low Prognostic Nutritional Index (PNI) Predicts Unfavorable Distant Metastasis-Free Survival in Nasopharyngeal Carcinoma: A Propensity Score-Matched Analysis. PLoS One. 2016 Jul 11;11(7):e0158853. doi: 10.1371/journal.pone.0158853. eCollection 2016. 37.He WZ, Rong YM, Jiang C, Liao FX, Yin CX, Guo GF, Qiu HJ, Zhang B, Xia LP. Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen.Chin J Cancer. 2016;35(1):58. doi: 10.1186/s40880-016-0120-4. 38.Yang Q, Liao F, Huang Y, Jiang C, Liu S, He W, Kong P, Zhang B, Xia L. Longterm effects of palliative local treatment of incurable metastatic lesions in colorectal cancer patients. Oncotarget. 2016 Apr 12;7(15):21034-45. 39.Jiang C, Hu WM, Liao FX, Yang Q, Chen P, Rong YM, Guo GF, Yin CX, Zhang B, He WZ, Xia LP. Elevated preoperative neutrophil-to-lymphocyte ratio is associated with poor prognosis in gastrointestinal stromal tumor patients. Onco Targets Ther. 2016;9:877-83.? 40.Liao F, He W, Jiang C, Yin C, Guo G, Chen X, Qiu H, Rong Y, Zhang B, Xu D, Xia L. A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C.Onco Targets Ther. 2015;8:3135-3142. 41.Yang Q, Yin C, Liao F, Huang Y, He W, Jiang C, Guo G, Zhang B, Xia L.Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer.Onco Targets Ther. 2015;8:2407-13.? 42.Chen ZY, He WZ, Peng LX, Jia WH, Guo RP, Xia LP（共同通訊）, Qian CN.A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients.Int J Cancer. 2015 Feb 1;136(3):584-92.? 43.He WZ, Yin CX, Jiang C, Guo GF, Rong RM, Qiu HJ, Chen XX, Zhang B, Xia LP. Prognostic Model Built on Blood-based Biomarkers in Patients with Metastatic Colorectal Cancer. Asian Pac J Cancer Prev. 2014; ;15(17):7327-31. 44.Yin C, Jiang C, Liao F, Rong Y, Cai X, Guo G, Qiu H, Chen X, Zhang B, He W, Xia L. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther. 2014;7:1415-22. 45.Jiang C, Liao FX, Rong RM, Yang Q, Yin CX, He WZ, Cai XY, Guo GF, Qiu HJ Chen XX, Zhang B, Xia LP. Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer. Asian Pac J Cancer Prev. 2014;15(13):5493-8. 46.He WZ, Guo GF, Yin CX, Jiang C, Wang F, Qiu HJ, Chen XX, Rong RM, Zhang B, Xia LP. γ-Glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer. Colorectal Dis. 2013 Aug;15(8):e443-52.? 47.He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, Chen X, Rong R, Zhang B, Xia L. Initial Neutrophil Lymphocyte Ratio Is Superior To Platelet Lymphocyte Ratio As An Adverse Prognostic and Predictive Factor In Metastatic Colorectal Cancer. Medical Oncology. 2013 Mar;30(1):439. 48.Wang F, He W, Qiu H, Wang X, Guo G, Chen X, Rong Y, Zhou F, Yin C, Yuan Z, Xia L. Lymph Node Ratio and pN Staging Show Different Superiority As Prognostic Predictors Depending on the Number of Lymph Nodes Dissected in Chinese Patients with Luminal A Breast Cancer. Clin Breast Cancer. 2012 Dec;12(6):404-11. 49.Wang F, Guo GF, Qiu HJ, He WZ, Zhou FF, Chen XX, Hu PL, Zhang B, Yin CX, Zhang L, Xia LP.Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer.Cancer Biol Med. 2012 Mar;9(1):38-43. 50.Guo GF, Jiang WQ, Zhang B, Cai YC, Xu RH, Wang F, Chen XX, Xia LP. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. World J Gastroenterol. 2011; 17(43): 4839-4846. 51.Zhou FF, Yan M, Guo GF, Wang F, Qiu HJ, Zheng FM, Zhang Y, Liu Q, Zhu XF, Xia LP*.Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity correlates with increase of Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol. 2011 Dec;28(4):1302-7. 52.Xia LP, Qiu HJ, Chen XX, Hu PL, Guo GF, Wang F, Zhou FF, He WZ, Zhang B, Zhang L. Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with Non-small cell lung cancer: a report of 12 cases. Med Oncol. 2011 Dec;28 Suppl 1:570-6. 53.Guo GF, Cai YC, Zhang B, Xu RH, Qiu HJ, Xia LP, Jiang WQ, Hu PL, Chen XX, Zhou FF, Wang F.Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol. 2011 Dec;28 Suppl 1:197-203.（共同通訊） 54.Zhou FF, Xia LP, Guo GF, Wang X, Yuan ZY, Zhang B, Wang F. Changes in Therapeutic Strategies in Chinese Male Patients with Breast Cancer: 40 Years of Experience in a Single Institute. Breast. 2010;19(6):450-5. 55.Xia LP, Zhou FF, Guo GF, Wang F, Wang X, Yuan ZY, Zhang B. Chinese Female Breast Cancer Patients Show A Better Overall Survival Than Their Male Counterparts. Chinese Medicine Journal. 2010;123(17):2347-2352. 56.Zhang B, He WZ, Zhou FF, Guo GF, Jiang C, Yin CX, Chen XX, Qiu HJ, Rong RM, Xia LP. A Potential Administration-time Dependent Effect of Bevacizumab in Improving Overall Survival and Increasing Metastasis in Metastatic Colorectal Cancer. Chemotherapy. 2013, 2:108. doi:10.4172/2167-7700.1000108 第一作者/通訊作者論文(非SCI) 57.Yin CX, Jiang C, Liao FX, Rong RM, He WZ,Cai XY, Guo GF, Qiu HJ Chen XX, Zhang B, Xia LP.The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting. Chinese-German Journal of Clinical Oncology. 2014;13(4): 169-173. 58.Qiu HJ, He WZ, Yin CX, Guo GF, Wang F, Zhou FF, Jiang C, Xia LP. The efficacy and its related issues of combination of bevacizumab and taxanes-based regimens in Chinese patients with metastatic breast cancer. Chinese-German Journal of Clinical Oncology. 2012;11(10): 585-591. 59.Wang F, Guo GF, Qiu HJ, He WZ, Zhou FF , Chen XX, Hu PL, Zhang B, Yin CX, Zhang L, Xia LP. Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer. Cancer Biology ＆ Medicine. 2012;9(1):38-43. 60.Wang F, Guo GF, Qiu HJ, Chen XX, Hui PL, Zhou FF, He WZ, Zhang B, Xia LP. Pemetrexed Monotherapy and Pemetrexed Plus Platinum Combination Therapy as Non-First-Line Treatments for Advanced Non-Small Cell Lung Cancer. Clin Oncol Cancer Res. 2011; 8(4): 235–241 61.Qiu HJ, He WZ, Chen XX, Guo GF, Wang F, Zhou FF, Xia LP. The pooled analysis of efficacy and safety profiles of bevacizumab in Chinese cancer patients. Chinese-German Journal of Clinical Oncology.2011;10(11): 621-625. 62.Zhou FF, ?Huang R, Jiang J, Wang F, ?He WZ, Guo GF, Xia LP. A meta-analysis based on case-control studies shows the similar prognosis between male and female patients with breast cancer. Chinese-German Journal of Clinical Oncology.2011;10(6): 311-316. 63.Qiu HJ, Wang F, Guo GF, Zhou FF, He WZ, Xia LP. Non-platinum doublets versus single agents in non-small cell lung cancer (NSCLC) patients with elderly age and/or poor performance status: a meta-analysis. Chinese-German Journal of Clinical Oncology. 2011;10(3): 134-139. 64.Wang F, Xia LP, Guo GF, Qiu HJ, Zhou FF, He WZ. The Pooled Analysis of Single Gemcitabine For Non-Small Cell Lung Cancer (NSCLC) Patients With Elderly Age. Chinese-German Journal of Clinical Oncology.2010;9(12):683-687. 65.丘惠娟,夏良平,汪芳,郭桂芳,周菲菲,張蓓,張力.Cetuximab聯(lián)合一線和非一線化療方案治療16 例非小細(xì)胞肺癌近期療效及其療效差異.南方醫(yī)科大學(xué)學(xué)報(bào).2010;30(11):2423-2426. 66.Wang F, Xia LP, Guo GF, et al. Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with Non-small cell lung cancer: a report of 6 cases. Chinese-German Journal of Clinical Oncology.2010;9(9):502-506.? 67.Xia LP, Yuan ZY, Wang X, et al. Characteristics of Chinese Male Patients with Breast Cancer: Summary of the Published Papers. Chinese-German Journal of Clinical Oncology.2010;9(6):311-315. 68.周菲菲,夏良平,王曦,郭桂芳,戎煜明,丘惠娟,張蓓.72例男性乳腺癌患者臨床病理特征和預(yù)后分析.中國腫瘤臨床. 2010;37(22):1296-1299. 69.Xia LP, Rong YM, Guo GF, et al. The summary of efficacy of cetuximab combination with chemotherapy in NSCLC first-line setting: based on publication. Chinese-German Journal of Clinical Oncology.2010;9(3):137-141. 70.丘惠娟,夏良平,徐瑞華,張蓓,郭桂芳,戎煜明,周菲菲,汪芳.含Cetuximab方案治療10例胃癌和食管癌的近期療效分析.腫瘤學(xué)雜志.2010;16(4):294-297. 71.周菲菲,夏良平,王曦,郭桂芳,戎煜明,丘惠娟,張蓓.影響男性乳腺癌預(yù)后的多因素分析—單中心72例臨床資料總結(jié).癌癥.2010;29(2):196-201. 72.夏良平,張力,張蓓,郭桂芳,丘惠娟,戎煜明,汪桃利,周菲菲.Cetuximab聯(lián)合化療治療非小細(xì)胞肺癌近期療效分析—附2例報(bào)告及文獻(xiàn)綜述.腫瘤學(xué)雜志.2010;16(2):133-138. 73.Xia LP, Guo GF,Zhang B, et al. Short-term Efficacy of Cetuximab-contained Regimen on Patients with Advanced Gastrointestinal (Noncolorectal) Cancer: Experiences of 16 Patients in Single Institute. Chinese-German Journal of Clinical Oncology.2009; 8(11):669-674. 74.Xia LP, Guo GF,Qiu HJ, et al. Efficacy and safety profiles of cetuximab in Chinese patients with colorectal cancer. Chinese-German Journal of Clinical Oncology.2009;8(9):526-530. 75.夏良平, 張蓓, 郭桂芳, 等. 鼻咽癌放療后殘留和復(fù)發(fā)頸淋巴結(jié)的分布規(guī)律. 中山大學(xué)學(xué)報(bào)（醫(yī)學(xué)科學(xué)版）.2009;30(supple 4):199-202. 76.夏良平,張蓓, 劉茂珍, 等.Cetuximab聯(lián)合放療或化療治療11例頭頸惡性腫瘤近期療效分析.癌癥.2009.28(9):977-982. 77.Xia LP, Zeng ZY, Guo ZM, Guo GF, Zhang B, Qiu HJ, Zhou FF. Neck dissection for recurrent and persistent lymph nodes of nasopharyngeal carcinoma after radiotherapy: effect and choice. Chinese-German Journal of Clinical Oncology.2009;8(2):81-85. 78.夏良平,張蓓,丘惠娟,等.鼻咽癌放療后頸淋巴結(jié)殘留與復(fù)發(fā)的療效差異.中山大學(xué)學(xué)報(bào)（醫(yī)學(xué)科學(xué)版）.2008;29(supple 3):41-44. 79.夏良平, 李秀英, 張?jiān)? 等. 人穿孔素?cái)U(kuò)增與表達(dá)分析. 腫瘤學(xué)雜志,2006;12(3):188-190. 80.華輝, 陳靜靜, 夏良平, 等. 腫瘤浸潤性T淋巴細(xì)胞ζ鏈異常表達(dá)在舌癌預(yù)后中的價(jià)值. 中國腫瘤. 2009,18(40):304-307. 81.夏良平, 曾宗淵, 陳直華, 等. 鼻咽癌放療后頸淋巴結(jié)復(fù)發(fā)和殘留的外科治療. 中華耳鼻咽喉科雜志, 2005,40(2):95-99. 82.Xia LP, Zeng ZY, Guo ZM, et al . The Value Of Pathological and Molecular Margins To Direct The Postoperative Treatments Of Laryngeal Carcinoma. The Chinese-German Journal of Clinical Ocology. 2005,4(1):56-60. 83.夏良平，曾宗淵，許光普，等. 喉鱗癌原發(fā)灶和切緣中P53蛋白表達(dá)對(duì)術(shù)后治療的指導(dǎo)價(jià)值.中華腫瘤雜志, 2003,25(6):558-561. 84.夏良平，許光普，曾宗淵，等. 喉鱗癌手術(shù)切緣eIF4E蛋白表達(dá)與預(yù)后的關(guān)系.中華耳鼻咽喉科雜志, 2003,38(2):139-142. 85.夏良平, 陳直華，陳忠平，等. 顱面聯(lián)合進(jìn)路切除顱底惡性腫瘤16例臨床總結(jié). 中國神經(jīng)腫瘤雜志,2004,2(1):62-66. 86.夏良平, 曾宗淵, 郭朱明, 等.喉鱗癌原發(fā)灶及無瘤手術(shù)切緣組織p53蛋白表達(dá)及其與預(yù)后的研究. 癌癥.2003; 22(1):77-82. 87.夏良平，曾宗淵，許光普，等.喉鱗癌病理學(xué)陰性切緣中eIF4E和P53蛋白檢測及其意義.腫瘤, 2003,23(6):505-507. 88.夏良平，曾宗淵，郭朱明，等. 喉癌術(shù)后頸淋巴結(jié)復(fù)發(fā)的多因素分析. 中華臨床醫(yī)學(xué)實(shí)踐雜志.2003;2(12):1057-1060. 89.夏良平，曾宗淵，許光普，等. 喉鱗癌原發(fā)灶中eIF4E和P53蛋白表達(dá)特征及意義. 臨床耳鼻咽喉科雜志.2003,17(增刊):35-37. 90.夏良平，曾宗淵，陳福進(jìn)，等.保留喉功能的治療方法在喉癌T3病例中的應(yīng)用探討. 癌癥, 2001,20(5):511-514. 91.夏良平, 李添應(yīng), 陳明遠(yuǎn),等. 鼻息肉患者鼻息肉組織及鼻分泌物中白細(xì)胞介素-5的測定.耳鼻咽喉－頭頸外科, 2001, 8(1):38-41. 92.夏良平, 曾宗淵, 魏茂文, 等. 影響喉癌生存率諸因素的單因素和多因素分析. 中國腫瘤.2002; 11(11):655-657.? 93.夏良平, 曾宗淵, 曾敬，等.eIF4E及其ser-209磷酸化蛋白在喉鱗癌中表達(dá)特征及意義. 中國腫瘤2004,13(3):171-173. 94.夏 良 平, 曾 宗 淵, 郭朱明，等. 喉癌三種不同頸淋巴結(jié)轉(zhuǎn)移狀態(tài)者生存率分析. 腫瘤. 2004,24(4):388-391. 95.夏良平，曾宗淵，陳直華，等.部分喉切除術(shù)中影響切緣結(jié)果的因素分析.腫瘤學(xué)雜志. 2004,10(4):220-222. （二）非第一作者論文 96.Chen P, Zhang B, Guo GF, Xia LP, Qiu HJ. Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases. Chinese-German Journal of Clinical Oncology.2014.13(5):229-234. 97.Sun T, Li D, Wang L, Xia L, Ma J, Guan Z, Feng G, Zhu X. c-Jun NH2-terminal kinase activation is essential for up-regulation of LC3 during ceramide-induced autophagy in human nasopharyngeal carcinoma cells. J Transl Med. 2011 Sep 26;9:161. 98.Deng R, Tang J, Xia LP, Li DD, Zhou WJ, Wang LL, Feng GK, Zeng YX, Gao YH, Zhu XF. ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway.Mol Cancer Ther. 2009;8(4):873-882.（IF=5.003） 99.Deng R, Tang J, Ma JG, Chen SP, Xia LP, Zhou WJ, Li DD, Feng GK, Zeng YX, Zhu XF.PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation.Oncogene. Oncogene. 2011 Feb 24;30(8):944-55. 100.Yao JE, Yan M, Guan Z, Pan CB, Xia LP, Li CX, Wang LH, Long ZJ, Zhao Y, Li MW, Zheng FM, Xu J, Lin DJ, Liu Q.Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival.Mol Cancer. 2009 Nov 5;8:95. （IF=5.362） 101.Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, Zhao Y, Huang XF, Wang XR, Zhu XF, Hong MH, Liu Q.Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells.Carcinogenesis. 2008;29(10):1930-1937. （IF=4.93） 102.郭桂芳,夏良平,徐瑞華,陳徐賢,汪 芳,何文卓,姜文奇.西妥昔單抗聯(lián)合化療治療晚期結(jié)直腸癌的生存分析及KRAS對(duì)療效的影響. 中山大學(xué)學(xué)報(bào)醫(yī)學(xué)科學(xué)版. 2011;32(5): 637-643. 103.郭桂芳,夏良平,丘惠娟,等.西妥昔單抗聯(lián)合化療治療102例K-ras狀態(tài)不明晚期結(jié)直腸癌的療效.中華腫瘤雜志.2010;32(10):777-781. 104.徐大志, 夏良平, 林桐榆, 等. 磷酸化的哺乳動(dòng)物雷帕霉素靶蛋白在胃癌組織中的表達(dá).中山大學(xué)學(xué)報(bào)醫(yī)學(xué)科學(xué)版. 2009;30(3): 304-307.? 105.李秀英, 夏良平, 賴延?xùn)|.人PFP、GrB共表達(dá)誘導(dǎo)喉癌Hep-2細(xì)胞凋亡的研究.免疫學(xué)雜志,2009;25(2):150-157. 106.李秀英,夏良平, 賴延?xùn)|.PFP、GrB的共表達(dá)殺傷人喉癌Hep-2細(xì)胞的體外研究.現(xiàn)代免疫學(xué). 2008; 28(3):224-228.? 107.李秀英, 夏良平, 賴延?xùn)|. PFP、GrB真核共表達(dá)載體的構(gòu)建及表達(dá)分析.中國免疫學(xué)雜志,2008,24(6):492-495. 108.陳明遠(yuǎn), 夏良平, 陳直華,等.植人式靜脈輸液港不同植人術(shù)式在惡性腫瘤患者中的應(yīng)用. 中山大學(xué)學(xué)報(bào)（醫(yī)學(xué)科學(xué)版）.2007;28(3S):145-147. 109.葉石敦, 夏良平, 賴延?xùn)|. 重組人顆粒酶B對(duì)胃癌細(xì)胞增殖的影響.山東醫(yī)藥,2006;46(6):15-16. 110.郭桂芳,夏良平,張蓓,姜文奇,丘惠娟,劉茂珍,胡丕麗,陳徐賢,周菲菲.西妥昔單抗聯(lián)合化療治療53例晚期結(jié)直腸癌的療效. 癌癥.2009;28(12):1317-1323. 111.曾宗淵，夏良平，陳福進(jìn)，等.術(shù)中留取切緣標(biāo)本對(duì)早期喉癌患者術(shù)后治療的指導(dǎo)價(jià)值. 中華耳鼻咽喉科雜志, 2001,36(4):250-253. 112.李添應(yīng), 夏良平, 陳明遠(yuǎn),等. 白細(xì)胞介素-5及嗜酸性粒細(xì)胞在鼻息肉中的相關(guān)性研究. 臨床耳鼻咽喉科雜志, 2000, 14(11):488-490. 113.李添應(yīng), 夏良平, 孟慶翔, 等.nm23-H1基因在鼻腔鼻竇內(nèi)翻性乳頭狀瘤及其癌變組織中的表達(dá). 臨床耳鼻咽喉科學(xué)雜志. 2004,18(2):86-87. 114.曾宗淵，夏良平，郭朱明，等.喉癌治療方法的選擇和失敗原因分析. 癌癥,2001, 20(11):1012-1015.? 115.李秀英, 賴延?xùn)|, 夏良平, 等. 人顆粒酶B基因的克隆、蛋白純化及表達(dá)分析. 現(xiàn)代免疫學(xué),.2004,24(6):486-489. 116.李秀英, 賴延?xùn)|, 夏良平, 等.人穿孔素基因真核表達(dá)載體的構(gòu)建與表達(dá)分析. 免疫學(xué)雜志, 2005,21(6):546 117.李添應(yīng), 邱前輝, 夏良平.功能性內(nèi)窺鏡鼻竇手術(shù)對(duì)嗅覺及嗅粘膜上皮形態(tài)的影響. 中山醫(yī)科大學(xué)學(xué)報(bào), 2000,21(6):473-477 118.許光普, 曾宗淵, 夏良平, 等. 部分喉切除術(shù)切緣病理學(xué)檢查對(duì)術(shù)后治療及預(yù)后估計(jì)的意義. 癌癥，2002，21（2）：200-203. 119.郭朱明, 曾宗淵, 夏良平,等.口底鱗狀細(xì)胞癌轉(zhuǎn)移性頸淋巴結(jié)分布特點(diǎn)及處理的探討. 癌 120.楊安奎, 陳福進(jìn),曾宗淵, 夏良平. 全喉切除術(shù)前喉裂開探查對(duì)病人預(yù)后的影響. 中國腫瘤, 2001,10(9):550-552. 121.郭朱明，曾宗淵，夏良平，等. 微波固化在口腔癌中的臨床應(yīng)用—附96例臨床總結(jié). 癌癥.2003; 22(1):71-76. 122.黃湛, 曾宗淵, 官梅, 夏良平. iNOS和bFGF在聲門上喉鱗癌中的表達(dá)及意義. 癌癥.2002; 21(9 ): 961－964. 123.黃湛, 曾宗淵, 彭漢偉, 夏良平，等.聲門上喉鱗癌組織中誘導(dǎo)型一氧化氮合酶和堿性成纖維細(xì)胞生長因子表達(dá)與預(yù)后的關(guān)系.癌癥. 2003,22(9):978－981. 124.張?jiān)? 曾宗淵, …夏良平.等.微波固化治療口腔癌的療效分析. 癌癥, 2001, 20(10):1100-1103. 125.郭朱明, 曾宗淵, 夏良平,等.口底鱗狀細(xì)胞癌轉(zhuǎn)移性頸淋巴結(jié)分布特點(diǎn)及處理的探討. 癌癥.2002; 21(9):979-982. 126.曾宗淵,張 詮,…夏良平.微波固化與外科手術(shù)治療口底癌的療效比較. 中華耳鼻咽喉科雜志, 2002,37(2):90－94. 127.許光普, 曾宗淵, 陳福進(jìn),… 夏良平.等. 新輔助化療治療晚期喉癌及喉咽癌的近期療效評(píng)定. 臨床腫瘤學(xué)雜志2002;7(6):413-415. （三）綜述及病例報(bào)道 128.江暢, 夏良平. 腫瘤干細(xì)胞糖代謝的研究進(jìn)展. 腫瘤學(xué)雜志,2014;20(3): 947-950. 129.陳平, 夏良平, 張蓓. 癌細(xì)胞中葡萄糖代謝與轉(zhuǎn)運(yùn)特點(diǎn). 腫瘤學(xué)雜志,2014;20(3):244-247. 130.尹晨希，周菲菲, 夏良平. 惡性腫瘤患者血清中PKM2水平的診斷和預(yù)后預(yù)測價(jià)值。腫瘤學(xué)雜志,2013;19(7):565-569. 131.Xia LP, Wu PH, Xia JC, Zhang B, Guan ZZ, Wan DS, Guo GF, Zeng YX. One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.Chin J Cancer. 2010 Dec;29(12):1023-8. 132.夏良平,郭桂芳.含西妥昔單抗方案治療胃癌和食管癌的近期療效.國際腫瘤學(xué)雜志,2010;37(3):217-219. 133.夏良平,周菲菲,楊名添,等. Aurora-A在乳腺癌致瘤機(jī)制和預(yù)后方面的研究進(jìn)展.癌癥.2009;28(7):668-672. 134.夏良平,周菲菲,劉強(qiáng). Aurora-A激酶抑制劑的抗腫瘤作用.臨床腫瘤學(xué)雜志.2009;10(10):941-945. 135.夏良平,周菲菲,楊名添,謝小明.乳腺癌中基因標(biāo)簽研究的共性問題. 國際腫瘤學(xué)雜志. 2009;36(4):280-282. 136.夏良平,周菲菲,曾宗淵. Cetuximab聯(lián)合放療和/或化療治療頭頸癌研究進(jìn)展.中華腫瘤防治雜志.2009;16(20 supple):74-77. 137.周菲菲,夏良平,王曦.真核起始因子4E在乳腺癌中的研究進(jìn)展.國際腫瘤學(xué)雜志. 2009;36(11):850-852.（通訊作者） 138.汪芳,夏良平.Cetuximab在晚期非小細(xì)胞肺癌一線治療中的研究進(jìn)展. 腫瘤學(xué)雜志. 2011;17(9):649-652. （通訊作者） 139.郭桂芳夏良平,姜文奇.自噬及其與結(jié)直腸癌的發(fā)生和治療. 國際腫瘤學(xué)雜志. 2010;37(10):774-777. 140.夏良平.喉癌誘導(dǎo)化療的臨床研究進(jìn)展. 耳鼻咽喉－頭頸外科, 2001,8(2):125-128.</div 詳細(xì)介紹